Cryptome and NTRI to Work on Brain Trauma Drugs
Using highly specialized clinical source materials from the NTRI, Cryptome will apply its proprietary Cryptomics(TM) drug discovery technology to find novel protein fragments (crypteins) which could potentially be used as drugs to prevent or limit damage from inflammatory or traumatic injury of the brain
While any drug candidates discovered will be owned by Cryptome, the agreement also gives NTRI the right to develop its own novel intellectual property from the libraries of protein fragments developed by Cryptome. With Cryptome as the commercial partner for all emerging drug candidates, both the business interests of Cryptome and the basic research interests of the NTRI will be significantly advanced.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.